If China — one of the few remaining countries in the world that haven’t introduced Hib vaccine in their national immunization program — decides to include the vaccine in their program, it could actually be cost saving; the vaccination costs would be less than the averted costs of illness from Hib meningitis and pneumonia, if a vaccine price matching UNICEF’s (US$2/dose) can be obtained. The vaccination will be cost-effective, but not cost saving, if the program pays the current market price in China of US$10 per dose.
Full Citation:
Ning G, Yin Z, Li Y et al. 2018. Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland China. Human Vaccines & Immunotherapeutics. 14(1).
Title of Article: Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland China
Author(s): Ning G, Yin Z, Li Y et al
Publication Year: 2018
Publication Name: Human Vaccines & Immunotherapeutics
Publication Volume: 14(1)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791576/pdf/khvi-14-01-1385687.pdf
DOI (Digital Object Identifier): 10.1080/21645515.2017.1385687
Topics: Economics & Return on Investment
Disease Vaccines: Haemophilus lnfluenzae type b (Hib)
Countries: China
WHO Regions: Western Pacific